5-Azacytidine Suppresses the Expression of Tissue-Specific Oct-1 Isoform in Namalwa Burkitt’s Lymphoma Cell Culture
-
Published:2022-04
Issue:1
Volume:503
Page:76-79
-
ISSN:1607-6729
-
Container-title:Doklady Biochemistry and Biophysics
-
language:en
-
Short-container-title:Dokl Biochem Biophys
Author:
Kotnova A. P.,Stepchenko A. G.,Ilyin Yu. V.,Georgieva S. G.,Pankratova E. V.
Abstract
Abstract
Overexpression of the transcription factor POU2F1 (Oct-1) increases the malignant potential of the tumor and determines the unfavorable prognosis for both solid and hematological cases of the disease in human carcinogenesis. The Oct-1 level determines the rate of development of the disease in acute myelodysplastic leukemia (AML), and a decrease in its expression significantly delays the development of leukemia in mice; however, a complete knockout of Oct-1 leads to the death of the animals. POU2F1 (Oct-1) is expressed as several isoforms transcribed from alternative promoters. They include both ubiquitous and tissue-specific isoforms. It was shown that in Burkitt’s lymphoma Namalwa cells 5-azacytidine specifically suppresses the expression of the tissue-specific isoform Oct-1L mRNA (level of Oct-1L is abnormally increased in these cells), while not causing changes in the amount of the ubiquitous isoform Oct-1A mRNA. These results show that it is possible to selectively reduce the transcription level of the Oct-1L isoform aberrantly expressed in human tumor cells.
Publisher
Pleiades Publishing Ltd
Subject
General Chemistry,Biochemistry,General Medicine,Biophysics
Reference18 articles.
1. Vázquez-Arreguín, K. and Tantin, D., The Oct1 transcription factor and epithelial malignancies: old protein learns new tricks, Biochim. Biophys. Acta, 2016, vol. 1859, no. 6, pp. 792–804. 2. Maddox, J., Shakya, A., South, S., et al., Transcription factor Oct1 is a somatic and cancer stem cell determinant, PLoS Genet., 2012, vol. 8, art. ID e1003048. 3. Shakya, A., Goren, A., Shalek, A., et al., Oct1 and OCA-B are selectively required for CD4 memory T cell function, J. Exp. Med., 2015, vol. 212, pp. 2115–2131. 4. Shakya, A., Cooksey, R., Cox, J.E., Wang, V., McClain, D.A., and Tantin, D., Oct1 loss of function induces a coordinate metabolic shift that opposes tumorigenicity, Nat. Cell Biol., 2009, vol. 11, no. 3, pp. 320–327. 5. Portseva, T.N., Pankratova, E.V., Stepchenko, A.G., and Georgieva, S.G., Increased level of Oct-1 protein in tumor cells modulates cellular response to anticancer drugs, Dokl. Biochem. Biophys., 2016, vol. 469, pp. 269–272.
|
|